Saatja: <
[email protected]>
Saadetud: 01.07.2019 17:01
Adressaat: Maris Jesse <
[email protected]>; Merike Jürilo
<
[email protected]>; <
[email protected]>;
<
[email protected]>; <
[email protected]>; Kärt Sõber
<
[email protected]>; <
[email protected]>; Kristin Raudsepp
<
[email protected]>; Rain Laane <
[email protected]>;
<
[email protected]>; <
[email protected]>; Annika Veimer
<
[email protected]>; <
[email protected]>
Koopia: <
[email protected]>; SM Info <
[email protected]>; info ravimiamet ee
<
[email protected]>; <
[email protected]>; <
[email protected]>; <
[email protected]>
Teema: Kokkuvõte apteegis puukentsefaliidi vastu vaktsineerimisest
Tähtsus: Tavaline
Manused: 2019. aastal apteegis puukentsefaliidi vastu vaktsineerimise tulemused.pdf; WHO
Q&A about H3N2 recommendation.pdf
Lugupeetud Sotsiaalministeerium, Terviseamet, Ravimiamet, Eesti Haigekassa ning Tervise
Arengu Instituut
Apteegis puukentsefaliidi vastu vaktsineerimine on selleks hooajaks lõppenud ning meil on hea
meel jagada Teiega kokkuvõtvat statistikat. 19 apteegis üle Eesti vaktsineeriti ajaperioodil
01.04.19 – 31.05.19 9132 inimest. Kokkuvõte on lisatud manusesse ning oleme valmis vastama
täiendavatele küsimustele.
Ühtlasi soovime Teid teavitada meieni jõudnud WHO informatsioonist, mille kohaselt 2019-
2020. a hooaja gripiviiruse tüvede lõplik väljaselgitamine sel aastal viibis. Sellest tulenevalt
hilinevad gripivaktsiini tarned Eestisse ning sügisese vaktsineerimise aktiivne periood lüheneb.
Eelneva valguses on meie hinnangul vajalik gripi vastu vaktsineerimine teha Eesti elanikkonna
jaoks taas kättesaadavamaks. Lisasime manusesse ka WHO sellekohase selgitava dokumendi.
EAÜ liikmed jälgivad murelikult leetritesse haigestumise tõusu Eesti elanikkonna seas ning
näeme, et selles erandlikus leetritesse haigestumise kasvu olukorras võiksid apteegid toetada
leetritevastast vaktsineerimist. Oleme valmis kaasa lööma leetritevastases vaktsineerimises,
korraldades vaktsineerimist apteekide ruumides, ning osalema elanikkonna teavitamises
leetritevastase vaktsineerimise olulisusest. Sarnaselt gripivastasele ja entsefaliidivastasele
vaktsineerimisele, viiks apteegiruumis vaktsineerimise praktilisi toiminguid jätkuvalt läbi
tervishoiuteenuse osutajate juures töötavad ja immuniseerimise täiendkoolituse läbinud
tervishoiutöötajad.
Toetudes nii teiste Euroopa riikide varasemale kui ka Eesti viimase aasta kogemusele, oleme
veendumusel, et apteegis vaktsineerimine tõstab elanikkonna üldist vaktsineerituse taset ning
kasvatab teadlikkust vaktsineerimise tähtsusest. Ühtlasi arvame, et vaktsineerimist toetava
apteegisektori vaktsineerimise edendamisele suunatud tegevused aitavad vähendada
ühiskonnas levivaid eksiarvamusi vaktsineerimisest.
Jääme ootama Teie tagasisidet.
Parimate soovidega
Timo Danilov
Juhatuse liige
MTÜ Eesti Apteekide Ühendus
Questions and Answers
A(H3N2) component of the recommended composition of influenza virus
vaccines for use in the northern hemisphere 2019-20 influenza season and
development of candidate vaccine viruses for pandemic preparedness
21 March 2019
1. What is the A(H3N2) component recommended for northern hemisphere 2019-2020
influenza season?
2. Why was there a delay in selecting the A(H3N2) virus component of 2019-20
influenza vaccines?
3. Is this the first time that a WHO recommendation for one component of seasonal
vaccine was postponed?
4. Will it be possible to avoid such postponement in the future?
5. What is the risk of delay of the supply of influenza vaccines for the upcoming
northern hemisphere season?
6. What is WHO GISRS doing to mitigate the risk of delayed vaccine supply and
availability?
7. What are countries expected to do to mitigate the risk?
1. What is the A(H3N2) component recommended for northern hemisphere 2019-2020
influenza season?
An A/Kansas/14/2017 (H3N2)-like virus was recommended for influenza vaccines for use in
the northern hemisphere 2019-2020 season. This recommendation was announced by WHO
on 21 March 2019 at:
https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/
2. Why was there a delay in selecting the A(H3N2) virus component of 2019-20
influenza vaccines?
Influenza A(H3N2) viruses have resented an increasing challenge for vaccine virus selection
due to frequent changes in the virus and difficulties in generating candidate vaccine viruses
for use in manufacturing. Experts at the WHO Consultation, which took place from 19-21
February 2019, reviewed various sources of data including virus surveillance, antigenic
characterization, and virus fitness forecasts, and identified multiple co-circulating influenza
A(H3N2) virus groups. The proportion of viruses in one antigenically distinct group was
Page 1 of 3
rapidly increasing in some countries, prompting a delay in the selection of the A(H3N2)
vaccine component to allow time for monitoring virus circulation and characterisation of
potential vaccine viruses.
3. Is this the first time that a WHO recommendation for one component of seasonal
vaccine was postponed?
It is not the first time such a postponement has occurred. At the time of the WHO influenza
vaccine consultation in February 2003, an antigenically distinguishable group of A(H3N2)
viruses (A/Fujian/411/2002-like) had emerged and was increasing in prevalence, but the
extent and speed of the increase was unclear and an appropriate candidate vaccine virus was
not available at the time. Therefore, the recommendation on the A(H3N2) component of the
vaccine was postponed and announced in March 2003.
4. Will it be possible to avoid such postponement in the future?
Although postponement of a decision is very rare, there may be occasions when it cannot be
avoided.
5. What is the risk of delay of the supply of influenza vaccines for the upcoming
northern hemisphere season?
Seasonal influenza vaccine production is a complicated just-in-time process with intrinsic
risks and challenges, affected by many factors, such as the yield of candidate vaccine viruses
and the availability of potency reagents. Through joint efforts from all players involved in the
process of influenza vaccine development, production and delivery, including WHO
Collaborating Centres(CCs) and WHO Essential Regulatory Laboratories (ERLs) of the
Global Influenza Surveillance and Response System(GISRS), national regulatory agencies
and vaccine manufacturers, the risk of delayed vaccine supply and availability will be
minimised as much as possible.
6. What is WHO GISRS doing to mitigate the risk of delayed vaccine supply and
availability?
WHO CCs, ERLs and reassorting laboratories are working intensively to develop,
characterise and make available a selection of candidate vaccine viruses (CVVs) for vaccine
manufacturers to enable selection of the highest yielding viruses for production. WHO ERLs
are committed to producing potency reagents for the A(H3N2) component in a timely manner.
The WHO Global Influenza Programme (GIP) is facilitating and coordinating key
stakeholders and ensuring smooth communication of the latest developments to vaccine
manufacturers and other interested bodies.
Page 2 of 3
7. What are countries expected to do to mitigate the risk?
Seasonal influenza vaccine campaign planning should continue routinely. It is recommended
that countries prepare for a potential scenario of delay (maximum of 2-4 weeks) in vaccine
supply and the possible extension of times allotted for vaccination programmes, meanwhile
continue to conduct health education to ensure smooth vaccination program in the upcoming
season.
Page 3 of 3
2019. aastal apteegis puukentsefaliidi vastu vaktsineerimise
tulemused
___________________________________________________________
Lühikokkuvõte vaktsineerimisest apteegis:
Ajaperioodil 01.04.2019 – 31.05.2019 viidi puukentsefaliidivastane vaktsineerimine läbi 19 Eesti apteegis
Tallinnas, Tartus, Pärnus, Rakveres, Kuressaares ja Jõhvis. Elanikkonda vaktsineeriti kahel kuni neljal
päeval nädalas, keskmiselt 3 tundi päevas. Vaktsineerimist teostas tervishoiuteenuse osutaja koosseisu
kuuluv tervishoiutöötaja (õde või ämmaemand), kes oli läbinud nõutava 16-tunnise immuniseerimise
täiendõppe ning viie aasta möödumisel läbinud ka 8-tunnise immuniseerimisalase täiendõppekursuse.
Vaktsineerimine viidi läbi apteegi pinnal asuvates muudest ruumidest eraldatud privaatsetes
nõustamisruumides. Vaktsineerimine dokumenteeriti kohapeal Tervise Infosüsteemis,
immuniseerimisraamatus ja lisaks vaktsineerimispassis või spetsiaalses infovoldikus.
Koondtulemused:
Projekti käigus koguti isikustamata andmeid vaktsineeritute kohta.
Rakvere
1. Projekti tulemusena vaktsineeriti 3%
Jõhvi
Pärnu 3%
kokku 9132 inimest (graafik 1), 6%
Kuressaare
kellest: 4%
Tallinnas 5610
Tartus 2088 Tallinn
Tartu
Kuressaares 359 23%
61%
Pärnus 518
Rakveres 246
Jõhvis 311 Tallinn Tartu Kuressaare Pärnu Rakvere Jõhvi
Graafik 1. Vaktsineeritute geograafiline jaotus
2. Sooliselt jaotusid vaktsineeritud
järgmiselt (graafik 2):
Naised 5149
Mees
Mehed 3983 44%
Naine
56%
Naine Mees
Graafik 2. Vaktsineeritute sooline jaotus
1
3. Vanuseliselt jaotusid vaktsineeritud
järgmiselt (graafik 3): Lapsed 0-14. a
21 %
Lapsed 0-14 a: 1931
Noorukid
Noorukid 15-17 a: 214 15-17 a
Täiskasvanud: 6987 2%
Täiskasvanud
77 %
Lapsed 0-14 a Noorukid 15-17 a Täiskasvanud
Graafik 3. Vaktsineeritute vanuseline jaotus
4. Esmavaktsineerijate ja re-vaktsineerijate
vahekord oli järgmine (graafik 4): Revaktsineerimine
22%
Esmavaktsineerijad 7136
Esmasvaktsineeri
Revaktsineerijad 1996 mine
78%
Esmasvaktsineerimine Revaktsineerimine
Graafik 4. Esmavaktsineerijate ja revaktsineerijate osakaal
Täiendav teave
1. Terviseameti andmetel vaktsineeris 2018. a II kvartalis puukentsefaliidi vastu 23751 inimest üle
Eesti (esmased vaktsineerijad + revaktsineerijad). Kui võrrelda 2019. a apteegis vaktsineeritud
inimeste arvu 2018. a II kvartalis vaktsineeritud inimeste arvuga üle Eesti, siis on apteegis
vaktsineeritud inimeste osakaaluks 38,4 %.
Lisainfo:
Eesti Apteekide Ühendus
Kristiina Sepp, juhatuse liige,
[email protected], +372 511 2195
Timo Danilov, juhatuse liige,
[email protected], +372 53 442 191
2